Drugging the undruggable RAS: Mission Possible?
Open accessThe DOI matches its Crossref record; 231 of the 231 references it cites were found in a registry or an index.
Abstract
Despite more than three decades of intensive effort, no effective pharmacological inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'. However, recent data from the laboratory and the clinic have renewed our hope for the development of RAS-inhibitory molecules. In this Review, we summarize the progress and the promise of five key approaches. Firstly, we focus on the prospects of using direct inhibitors of RAS. Secondly, we address the issue of whether blocking RAS membrane association is a viable approach. Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favourable current approach. Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise. Finally, RAS-mediated changes in cell metabolism have recently been described and we discuss whether these changes could be exploited for new therapeutic directions. We conclude with perspectives on how additional complexities, which are not yet fully understood, may affect each of these approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“KRAS has historically been considered ‘undruggable’ owing to a lack of pharmacologically targetable pockets within the mutant isoforms.”
From The current state of the art and future trends in RAS-targeted cancer therapies (2022) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Genetic analysis has shown that 98% of RAS mutations that cause cancer are concentrated in three residues: G12, G13, and Q61.”
From The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives (2025) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A number of highly selective and potent inhibitors have been developed against kinases in the Ras signaling network particularly those in the MAPK and PI3K/mTOR pathways (9, 12).”
From KRAS mutation in pancreatic cancer (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For more than 40 years, KRAS mutation has been considered “undruggable” [16, 17].”
From Targeting KRAS mutant cancers: from druggable therapy to drug resistance (2022) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For many proteins known to be involved in driving diseases, such as KRAS in many cancers, conventional drug development strategies often aimed at developing inhibitors have failed [118, 119].”
From Advances in targeted degradation of endogenous proteins (2019) · cites this paper as [119]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Genome-scale CRISPR-Cas9 knockout screening in human cells
Shalem, O., Sanjana, N. E., Hartenian, E., Shi, X., Scott, D. A., Mikkelsen, T. S., Heckl, D., Ebert, B. L., Root, D. E., Doench, J. G., et al. (2014) · Science · doi:10.1126/science.1247005 · Cited by 5,234
Wilhelm, S. M., Carter, C., Tang, L., Wilkie, D., McNabola, A., Rong, H., Chen, C., Zhang, X., Vincent, P., McHugh, M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1443 · Cited by 4,017
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,890
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
Research works printed but not linked: 1
- Kumar, M. S. et al. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell 149, 642–655 (2012). · DOI · Paper page
Cited by
Items 401–500 of 1,007
Burns, T. F., Borghaei, H., Ramalingam, S. S., Mok, T. S. K., & Peters, S. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00744 · Cited by 65
“This has made targeting RAS and KRAS extremely challenging in the clinic.(9,11,17)”
BackgroundInfluentialA proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies
Liu, Z., Liu, Y., Qian, L., Jiang, S., Gai, X., Ye, S., Chen, Y., Wang, X., Zhai, L., Xu, J. Q., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.07.021 · Cited by 58
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism
Peng, D. H., Kundu, S. T., Fradette, J. J., Diao, L., Tong, P., Byers, L. A., Wang, J., Canales, J. R., Villalobos, P. A., Mino, B., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1238 · Cited by 53
Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells
Lee, W., Lee, J. H., Jun, S., Lee, J. H., & Bang, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-30205-2 · Cited by 53
Designed covalent allosteric modulators: an emerging paradigm in drug discovery
Lu, S., & Zhang, J. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.013 · Cited by 55
Post-translational modification of KRAS: potential targets for cancer therapy
Wang, W., Yuan, T., Qian, M., Yan, F., Yang, L., He, Q., Yang, B., Lu, J., & Zhu, H. (2020) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00542-y · Cited by 59
Kim, Y., Jung, K., Beak, D., Hong, S.-S., & Kim, Y. (2016) · Oncogene · doi:10.1038/onc.2016.407 · Cited by 60
MicroRNA-30a attenuates mutant KRAS-driven colorectal tumorigenesis via direct suppression of ME1
Shen, H., Xing, C., Cui, K., Li, Y., Zhang, J., Du, R., Zhang, X., & Li, Y. (2017) · Cell Death and Differentiation · doi:10.1038/cdd.2017.63 · Cited by 55
“KRAS protein has been regarded as an ‘undruggable’ target.(5,6) Thus it has been suggested that taking advantage of synthetic lethal interactions with KRAS mutation could be exploited as an effective therapeutic strategy in KRAS-mutant human cancers.”
BackgroundCharitou, T., Srihari, S., Lynn, M. A., Jarboui, M. A., Fasterius, E., Moldovan, M. V., Shirasawa, S., Tsunoda, T., Ueffing, M., Xie, J., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0477-7 · Cited by 61
Parkin, A., Man, J., Timpson, P., & Pajic, M. (2019) · FEBS Journal · doi:10.1111/febs.15011 · Cited by 58
40 Years of RAS—A Historic Overview
Fernández‐Medarde, A., Rivas, J. D. L., & Santos, E. (2021) · Genes · doi:10.3390/genes12050681 · Cited by 61
“The lack of effectiveness of FTIs in clinical trials, together with the absence of discernible pockets on the RAS surface allowing direct binding of inhibitor, led to the assumption that RAS could be “undruggable” and for many years the search for drugs against RAS-driven tumors focused on the inhibition of downstream…”
BackgroundT Cell Recognition of Tumor Neoantigens and Insights Into T Cell Immunotherapy
Sim, M. J. W., & Sun, P. D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.833017 · Cited by 57
“These mutations occur in ‘hotspots’ at positions 12, 13 and 61 of RAS protein and lead to constitutive RAS activation promoting tumor transformation (20, 54).”
BackgroundCai, W., Luo, T., Chen, X., Mao, L., & Wang, M. (2022) · Advanced Functional Materials · doi:10.1002/adfm.202204947 · Cited by 54
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges
Choucair, K., Imtiaz, H., Uddin, M. H., Nagasaka, M., Al-Hallak, M. N., Philip, P. A., El-Rayes, B., Pasche, B., & Azmi, A. S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02473-8 · Cited by 79
Chakrabarti, M., Jang, H., & Nussinov, R. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5b11110 · Cited by 59
Targeting the RAS-dependent chemoresistance: The Warburg connection
Serna-Blasco, R., Sanz-Álvarez, M., Aguilera, Ó., & García-Foncillas, J. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.016 · Cited by 52
KRAS: Reasons for optimism in lung cancer
Lindsay, C. R., Jamal-Hanjani, M., Forster, M., & Blackhall, F. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.001 · Cited by 51
“Second, it is structurally a relatively smooth protein, with few clefts for potential lead compounds to ‘hook’ on to in order to exert their effects [1].”
BackgroundKaragiannakos, A., Adamaki, M., Tsintarakis, A., Vojtěšek, B., Fåhræus, R., Zoumpourlis, V. C., & Karakostis, K. (2022) · Cancers · doi:10.3390/cancers14030664 · Cited by 62
Chen, P., Yang, W., Hong, T., Miyazaki, T., Dirisala, A., Kataoka, K., & Cabral, H. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121748 · Cited by 52
Issahaku, A. R., Salifu, E. Y., Agoni, C., Alahmdi, M. I., Abo-Dya, N. E., Soliman, M. E. S., Rudrapal, M., & Naresh, P. (2023) · ChemistrySelect · doi:10.1002/slct.202300277 · Cited by 58
de Jager, V. D., Timens, W., Bayle, A., Botling, J., Brčić, L., Büttner, R., Fernandes, M. G. O., Havel, L., Hochmair, M. J., Hofman, P. M., et al. (2024) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2024.100838 · Cited by 73
“46 However, in 2013, the discovery of the switch-II pocket in KRAS G12C provided a breakthrough for the development of clinically effective KRAS G12C inhibitors.”
BackgroundEmerging Targets in Non-Small Cell Lung Cancer
Liu, L., Soler, J., Reckamp, K. L., & Sankar, K. N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810046 · Cited by 64
“KRAS mutations are the most frequently detected gain-of-function mutations found in LUAD and have been historically considered “undruggable” [14].”
BackgroundG4 DNA in ras genes and its potential in cancer therapy
Cogoi, S., & Xodo, L. E. (2016) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2016.02.002 · Cited by 57
Nakagawa, R., Muroyama, R., Saeki, C., Goto, K., Kaise, Y., Koike, K., Nakano, M., Matsubara, Y., Takano, K., Ito, S., et al. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.02.002 · Cited by 52
“Almost all Ras inhibitors target and suppress prenylations (mainly farne-syl transferase) in the Ras activation cascade and affect the entire Ras family [48].”
The importance of Ras in drug resistance in cancer
Healy, F. M., Prior, I. A., & MacEwan, D. J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15420 · Cited by 53
“…nucleotide binding site (where GTP or GDP binds) seems a desirable pocket to target, however the picomolar affinity with which both GDP and GTP bind, as well as their high intracellular concentrations, effectively outcompetes the binding of any drug at this site (Cox et al., 2014; McCormick, 2018).”
BackgroundChida, K., Kotani, D., Masuishi, T., Kawakami, T., Kawamoto, Y., Kato, K., Fushiki, K., Sawada, K., Kumanishi, R., Shirasu, H., et al. (2021) · The Oncologist · doi:10.1002/onco.13870 · Cited by 50
“RAS mutations are undruggable targets because of the presence of large, deep-seated hydrophobic pockets in their molecular structure that are difficult to target with small-molecule chemistry [6]; however, the development of small-molecule inhibitors that selectively bind to a newly discovered allosteric regulatory si…”
BackgroundŠolman, M., Ligabue, A., Blaževitš, O., Jaiswal, A., Zhou, Y., Liang, H., Lectez, B., Kopra, K., Guzmán, C., Härmä, H., et al. (2015) · eLife · doi:10.7554/elife.08905 · Cited by 50
“Ras hyperactivation is a hallmark of cancer and has long been considered to be pharmacologically intractable (Cox et al., 2014).”
The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior
Weinberg, F., Reischmann, N., Fauth, L., Taromi, S., Mastroianni, J., Köhler, M., Halbach, S., Becker, A. C., Deng, N., Schmitz, T., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.04.015 · Cited by 54
“This is an open access article under Indeed,mutations in the three hitherto undruggable RASproteins (KRas, N-Ras, H-Ras) represent major drivers in cancer, leading to chronic activation of the PI3K-AKT and RAF-MEK-ERK pathways (Cox et al., 2014; Eser et al., 2013; Hayes et al., 2016; Rajalingamet al., 2007).”
BackgroundInfluentialTherapeutic Targeting of mTOR in T-Cell Acute Lymphoblastic Leukemia: An Update
Evangelisti, C., Chiarini, F., McCubrey, J. A., & Martelli, A. M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071878 · Cited by 55
“RAS genes are the most frequently mutated genes in human cancer [62].”
BackgroundStructural impact of GTP binding on downstream KRAS signaling
Menyhárd, D. K., Pálfy, G., Orgován, Z., Vida, I., Keserű, G. M., & Perczel, A. (2020) · Chemical Science · doi:10.1039/d0sc03441j · Cited by 58
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine
Matrone, A., Gambale, C., Prete, A., & Elisei, R. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.864253 · Cited by 58
Ahn, D. H., Barzi, A., Ridinger, M., Samuëlsz, E., Subramanian, R. A., Wu, C.-C., Croucher, P. J. P., Smeal, T., Kabbinavar, F. F., & Lenz, H.-J. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3053 · Cited by 49
“Efforts for targeting KRAS in colorectal cancer and other cancers has had very limited progress so far (9), with the exception of the recent success in targeting KRAS-G12C, a relatively rare mutation in colorectal cancer (6, 10).”
RAS and RHO family GTPase mutations in cancer: twin sons of different mothers?
Hodge, R. G., Schaefer, A., Howard, S. V., & Der, C. J. (2020) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2020.1810622 · Cited by 52
Self-citationAnnual review of KRAS inhibitors in 2022
Wang, H., Chi, L., Yu, F., Dai, H., Gao, C., Si, X., Wang, Z., Liu, L., Zheng, J., Shan, L., et al. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115124 · Cited by 57
Yoon, C., Till, J. E., Cho, S., Chang, K. K., Lin, J.-X., Huang, C., Ryeom, S. W., & Yoon, S. S. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0077 · Cited by 50
“" Because RAS GTPases including KRAS are difficult to target directly with drugs because of structure-function considerations (26), we inhibited the KRAS pathway using an MEK inhibitor.”
MethodRetractedOu, A., Schmidberger, J. W., Wilson, K. A., Evans, C. W., Hargreaves, J. A., Grigg, M. C., O’Mara, M. L., Iyer, K. S., Bond, C. S., & Smith, N. M. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa262 · Cited by 53
“KRAS binds its GDP / GTP substrate in high (picomolar) affinity, and it is perhaps the one reason why designing an inhibitor is difficult (14,15).”
HDAC10 Regulates Cancer Stem-Like Cell Properties in KRAS-Driven Lung Adenocarcinoma
Li, Y., Zhang, X., Zhu, S., Dejene, E. A., Peng, W., Sepulveda, A. R., & Seto, E. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3613 · Cited by 50
Li, L., Wu, Y., Yang, Z., Xu, C., Zhao, H., Liu, J., Chen, J., & Chen, J. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105447 · Cited by 48
Toward a More Precise Future for Oncology
Murciano-Goroff, Y. R., Taylor, B. S., Hyman, D. M., & Schram, A. M. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.014 · Cited by 48
Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition
Yan, L., Tu, B., Yao, J., Gong, J., Carugo, A., Bristow, C. A., Wang, Q., Zhu, C., Dai, B., Kang, Y., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3792 · Cited by 48
Yu, Z., Hu, P., Xu, Y., Bao, Q., Ni, D., Wei, C., & Shi, J. (2020) · Small · doi:10.1002/smll.201907233 · Cited by 47
Boumelha, J., de Castro, A., Bah, N. K., Cha, H., Trécesson, S. D. C., Rana, S., Tomaschko, M., Anastasiou, P., Mugarza, E., Moore, C., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2627 · Cited by 57
Ras Dimer Formation as a New Signaling Mechanism and Potential Cancer Therapeutic Target
Chen, M., Peters, A., Huang, T., & Nan, X. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666151001152212 · Cited by 54
“To date, however, efforts to pharmacologically inhibit mutant Ras in human cancers have met with little success [23-25].”
BackgroundMembrane orientation dynamics of lipid-modified small GTPases
Prakash, P., & Gorfe, A. A. (2017) · Small GTPases · doi:10.1080/21541248.2016.1211067 · Cited by 48
A KRAS GTPase K104Q Mutant Retains Downstream Signaling by Offsetting Defects in Regulation
Yin, G., Kistler, S., George, S. D., Kuhlmann, N., Garvey, L., Huynh, M., Bagni, R. K., Lammers, M., Der, C. J., & Campbell, S. L. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.762435 · Cited by 47
“The most common RAS mutations identified in cancer occur at residues 12, 13, and 61 and render RAS GAP defective, thereby populating RAS in its active GTP-bound state (3).”
Self-citationSelective targeting of point-mutated KRAS through artificial microRNAs
Acunzo, M., Romano, G., Nigita, G., Veneziano, D., Fattore, L., Laganà, A., Zanesi, N., Fadda, P., Fassan, M., Rizzotto, L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1620562114 · Cited by 53
“KRAS targeting represents a particularly important opportunity for impacting cancer therapy, given that KRAS mutations are involved in the development of several types of cancers (3).”
BackgroundPalmioli, A., Ciaramelli, C., Tisi, R., Spinelli, M., Sanctis, G. D., Sacco, E., & Airoldi, C. (2017) · Chemistry - An Asian Journal · doi:10.1002/asia.201700844 · Cited by 55
Specific targeting of point mutations in EGFR L858R-positive lung cancer by CRISPR/Cas9
Cheung, A. H. K., Chow, C., Zhang, J., Zhou, Y., Huang, T., Ng, K. C.-K., Or, T. C. T., Yao, Y. Y., Dong, Y., Fung, J. M.-W., et al. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0056-1 · Cited by 56
“To overcome this obstacle, newer approaches, such as the application of synthetic lethality, have emerged [2, 13].”
MethodCermakova, K., & Hodges, H. C. (2018) · Molecules · doi:10.3390/molecules23081958 · Cited by 48
“High-throughput DNA-methylation profiling techniques uncovered that global hypomethylation is accompanied by increased promoter methylation of genes that are established tumor suppressors (such as BRCA1 [26,27], p16/INK4a [28], RASSF1A [29], and MLH1 [30]) and results in their silencing in different cancer types [31–3…”
BackgroundTargeting plasma membrane phosphatidylserine content to inhibit oncogenic KRAS function
Kattan, W. E., Chen, W., Ma, X., Lan, T.-H., van der Hoeven, D., van der Hoeven, R., & Hancock, J. F. (2019) · Life Science Alliance · doi:10.26508/lsa.201900431 · Cited by 46
“This regulatory circuit is subverted in 15 – 20% of all human tumors that express oncogenic RAS with mutations at residues 12, 13, or 61 (Cox et al, 2014).”
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Scheiblecker, L., Kollmann, K., & Sexl, V. (2020) · Pharmaceuticals · doi:10.3390/ph13120418 · Cited by 55
“Ras has long been considered undruggable, due to the absence of any deep hydrophobic pocket on its surface that could serve as a binding site for a small molecular inhibitor [33,120].”
BackgroundEfficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing
Sayed, S., Sidorova, O. A., Hennig, A., Augsburg, M., Cortés Vesga, C. P., Abohawya, M., Schmitt, L. T., Sürün, D., Stange, D. E., Mircetic, J., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-2519 · Cited by 46
“However,despitemore thanthreedecadesofintenseresearchefforts,targetingKRAShasproven challengingowingtoitssmallsize( (cid:1) 21 kDa, 189 amino acids) and a “ smooth ” surface that impedes binding by small molecules (2).”
Functional and biological heterogeneity of KRAS Q61 mutations
Huynh, M. V., Hobbs, G. A., Schaefer, A., Pierobon, M., Carey, L. M., Diehl, J. N., DeLiberty, J. M., Thurman, R. D., Cooke, A. R., Goodwin, C. M., et al. (2022) · Science Signaling · doi:10.1126/scisignal.abn2694 · Cited by 46
“Across all cancer types, the predominant mutation hotspot in KRAS is at codon G12, which accounts for 83% of all KRAS mutations but only 23% of all NRAS mutations (4).”
BackgroundInfluentialSelf-citationDiscovery of MK-1084: An Orally Bioavailable and Low-Dose KRAS G12C Inhibitor
Ma, X., Sloman, D. L., Duggal, R., Anderson, K. D., Ballard, J. E., Bharathan, I., Brynczka, C., Gathiaka, S. M., Henderson, T. J., Lyons, T. W., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c00572 · Cited by 53
Repurposing bacterial toxins for intracellular delivery of therapeutic proteins
Beilhartz, G. L., Sugiman‐Marangos, S. N., & Melnyk, R. A. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.04.009 · Cited by 55
Gash, K. J., Chambers, A. C., Cotton, D. E., Williams, A. C., & Thomas, M. G. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.175 · Cited by 47
“G-proteins such as RAS, important in colorectal cancer (Cox et al, 2014), undergo post-translational prenylation and early work suggested that RAS activation could be blocked by targeting this pathway (Schafer et al, 1989).”
BackgroundFluorescent light-up acridine orange derivatives bind and stabilize KRAS-22RT G-quadruplex
Carvalho, J., Pereira, E., Marquevielle, J., Campello, M. P. C., Mergny, J., Paulo, A., Salgado, G. F. J., Queiroz, J. A., & Cruz, C. (2017) · Biochimie · doi:10.1016/j.biochi.2017.11.004 · Cited by 47
Atomic structure of the eukaryotic intramembrane RAS methyltransferase ICMT
Diver, M. M., Pedi, L., Koide, A., Koide, S., & Long, S. B. (2018) · Nature · doi:10.1038/nature25439 · Cited by 47
An Integrated Global Analysis of Compartmentalized HRAS Signaling
Santra, T., Herrero, A., Rodríguez, J., von Kriegsheim, A., Iglesias-Martinez, L. F., Schwarzl, T., Higgins, D. G., Aye, T., Heck, A. J. R., Calvo, F., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.038 · Cited by 49
Revisiting the Role of Exosomes in Colorectal Cancer: Where Are We Now?
Mannavola, F., Salerno, T., Passarelli, A. M., Tucci, M., Internò, V., & Silvestris, F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00521 · Cited by 54
“Therapeutic Applications One of the major unmet issues in CRC is targetingmutated forms of RAS kinases since these are considered largely undruggable (76).”
BackgroundMembrane curvature sensing of the lipid-anchored K-Ras small GTPase
Hong, L., Mu, H., Jean-Francois, F. L., Lakshman, B., Sarkar‐Banerjee, S., Zhuang, Y., Zeng, Y., Gao, W., Zaske, A. M., Nissley, D. V., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201900343 · Cited by 49
“K-Ras is the most prevalent Ras isoform in cancer, and its oncogenic mutations contribute to ~80% of all Ras-related cancers (67).”
BackgroundKenney, C. M., Kunst, T. F., Webb, S., DeVisser, C., Arrowood, C., Steinberg, S. M., Mettu, N. B., Kim, E. J.-H., & Rudloff, U. (2021) · Investigational New Drugs · doi:10.1007/s10637-020-01044-8 · Cited by 48
Danesi, R., Fogli, S., Indraccolo, S., Re, M. D., Tos, A. P. D., Leoncini, L., Antonuzzo, L., Bonanno, L., Guarneri, V., Pierini, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100040 · Cited by 56
Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
Indini, A., Rijavec, E., Ghidini, M., Cortellini, A., & Grossi, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050653 · Cited by 51
“RAS family proteins are encoded by the highly homologous genes HRAS, NRAS, KRAS4A, and KRAS4B, of which activating mutations are involved in ~25% of all human cancers [8].”
BackgroundJain, A. S., Prasad, A., Pradeep, S., Dharmashekar, C., Achar, R. R., Silina, E. V., Stupin, V. A., Amachawadi, R. G. G., Prasad, S. K., Pruthvish, R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.741326 · Cited by 58
“Oncogenic Ras mutants have been termed “undruggable” for decades, because of their high affinity for GTP and absence of a suitable binding site for small molecule inhibitors to bind (39).”
BackgroundBrito, H., Martins, A. C., Lavrado, J., Mendes, E., Francisco, A. P., Santos, S. A., Ohnmacht, S. A., Kim, N. S., Rodrigues, C. M. P., Moreira, R., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126891 · Cited by 46
“The importance of therapeutic modulation of KRAS signaling have been widely recognized and several approaches have been reported in the past, but none has provided an approved new anticancer drug to date [5].”
BackgroundAdaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells
Chen, P.-Y., Muzumdar, M. D., Dorans, K. J., Robbins, R., Bhutkar, A., del Rosario, A., Mertins, P., Qiao, J., Schafer, A. C., Gertler, F., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2129 · Cited by 46
Blocking Ras inhibition as an antitumor strategy
Marín‐Ramos, N. I., Ortega‐Gutiérrez, S., & López-Rodríguez, M. L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.01.017 · Cited by 50
The diamond anniversary of tissue transglutaminase: a protein of many talents
Katt, W. P., Antonyak, M. A., & Cerione, R. A. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.037 · Cited by 44
KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer
Kang, Y. W., Lee, J. E., Jung, K. H., Son, M. K., Shin, S., Kim, S., Fang, Z., YAN, H. H., Park, J. H., Han, B., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.013 · Cited by 45
RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications
Saeed, O. A. M., Antonio Lopez-beltran, B., Fisher, K. W., Scarpelli, M., Montironi, R., Cimadamore, A., Massari, F., Santoni, M., & Liang Cheng, C. (2018) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2018-205471 · Cited by 48
Targeting the Tumor Microenvironment: An Unexplored Strategy for Mutant KRAS Tumors
Carvalho, P. D., Machado, A. L., Martins, F., Seruca, R., & Velho, S. (2019) · Cancers · doi:10.3390/cancers11122010 · Cited by 51
“, RAF, MEK, or PI3K) did not produce major clinical benefits, where induction of compensatory mechanisms that reactivate the pathway or even activation of alternative KRAS signaling effectors may account for resistance mechanisms [10,11].”
BackgroundZhou, Y., Prakash, P., Hong, L., Gorfe, A. A., & Hancock, J. F. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2014605118 · Cited by 51
Kattan, W. E., Liu, J., Montufar‐Solis, D., Hong, L., Barathi, B. B., van der Hoeven, R., Zhou, Y., & Hancock, J. F. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2114126118 · Cited by 47
LRRK2 as a target for modulating immune system responses
Russo, I., Bubacco, L., & Greggio, E. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105724 · Cited by 51
“that GTP competitive inhibitors have more off-target effects compared to ATP competitors (Cox et al., 2014), at least in small GTPases, these observations strengthen the idea that LRRK2-linked inflammation could represent a therapeutic target for diseases with a neuroinflammatory component.”
Parameswaran, N., Bartel, C. A., Hernandez-Sanchez, W. M., Miskimen, K. L. S., Smigiel, J. M., Khalil, A. M., & Jackson, M. W. (2019) · Scientific Reports · doi:10.1038/s41598-019-49475-5 · Cited by 49
CRAF dimerization with ARAF regulates KRAS-driven tumor growth
Venkatanarayan, A., Liang, J., Yen, I., Shanahan, F., Haley, B., Phu, L., Verschueren, E., Hinkle, T. B., Kan, D., Segal, E., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110351 · Cited by 50
Lipid Nanoparticle Delivery of Small Proteins for Potent In Vivo RAS Inhibition
Haley, R. M., Chan, A., Billingsley, M. M., Gong, N., Padilla, M. S., Kim, E. H., Wang, H. H., Yin, D., Wangensteen, K. J., Tsourkas, A., et al. (2023) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.3c01501 · Cited by 46
Thummalapalli, R., Bernstein, E., Herzberg, B. O., Li, B. T., Iqbal, A. N., Preeshagul, I. R., Santini, F. C., Eng, J., Ladanyi, M., Yang, S., et al. (2023) · JCO Precision Oncology · doi:10.1200/po.23.00030 · Cited by 61
Zhou, C., Fan, Z., Gu, Y., Ge, Z., Tao, Z., Cui, R., Li, Y., Zhou, G., Huo, R., Gao, M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01622 · Cited by 45
Targeting the RAS upstream and downstream signaling pathway for cancer treatment
Hossain, M. A. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176727 · Cited by 57
The role of S‐acylation in protein trafficking
Daniotti, J. L., Pedro, M. P., & Taubas, J. V. (2017) · Traffic · doi:10.1111/tra.12510 · Cited by 47
“all human cancers, which has led to intensive research aimed at interfering with the Ras function.(54,55)”
BackgroundHRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer
Sugita, S., Enokida, H., Yoshino, H., Miyamoto, K., Yonemori, M., Sakaguchi, T., Osako, Y., & Nakagawa, M. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4435 · Cited by 49
“Additionally, development of specific and competitive nucleotide inhibitors is challenging, because RAS binds nucleotide ligands with high affinity (10).”
Enhanced nanoparticle delivery exploiting tumour-responsive formulations
Bennie, L. A., McCarthy, H. O., & Coulter, J. A. (2018) · Cancer Nanotechnology · doi:10.1186/s12645-018-0044-6 · Cited by 50
Regulation of Dynamic Protein S-Acylation
Chen, J. J., Fan, Y., & Boehning, D. F. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.656440 · Cited by 55
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma
Lindsay, C. R., Garassino, M. C., Nadal, E., Öhrling, K., Scheffler, M., & Mazières, J. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.07.005 · Cited by 44
Targeting mutated GTPase KRAS in tumor therapies
Fan, G., Lou, L., Song, Z., Zhang, X., & Xiong, X. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113816 · Cited by 48
Pei, H., Guo, W., Peng, Y., Xiong, H., & Chen, Y. (2022) · Medicinal Research Reviews · doi:10.1002/med.21886 · Cited by 46
“, TFs), it is hard to develop modulators to target substrate sites.(13,360,361) While the allosteric modulators can regulate the protein activity without directly binding to the substrate site.”
BackgroundRAS oncogenic activity predicts response to chemotherapy and outcome in lung adenocarcinoma
East, P., Kelly, G. P., Biswas, D., Marani, M., Hancock, D. C., Creasy, T. H., Sachsenmeier, K. F., Swanton, C., Downward, J., & Trécesson, S. D. C. (2022) · Nature Communications · doi:10.1038/s41467-022-33290-0 · Cited by 43
Glimmers of hope for targeting oncogenic KRAS-G12D
Tang, D., & Kang, R. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00561-3 · Cited by 62
“The most hotspot oncogenic KRAS mutations are at position 12 (especially G12D, G12V, and G12C), which are constitutively activated due to their defective ability to hydrolyze guanosine triphosphate (GTP), leading to activation of the downstream RAF-MEK-ERK and PI3K-AKT-MTOR pathways [4].”
BackgroundInfluentialMore to the RAS Story: KRAS G12C Inhibition, Resistance Mechanisms, and Moving Beyond KRAS G12C
Lietman, C. D., Johnson, M. L., McCormick, F., & Lindsay, C. R. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351333 · Cited by 44
Role of RAS signaling in ovarian cancer
Therachiyil, L., Anand, A., Azmi, A., Bhat, A. A., Korashy, H. M., & Shahab Uddin, M. S. (2022) · F1000Research · doi:10.12688/f1000research.126337.1 · Cited by 54
Shi, J., Chen, Y., Peng, C., Kuang, L., Zhang, Z., Li, Y., & Huang, K. (2022) · ONCOLOGIE · doi:10.32604/oncologie.2022.027545 · Cited by 48
USP7 deubiquitinates KRAS and promotes non-small cell lung cancer
Huang, B., Cao, D., Yuan, X., Xiong, Y., Chen, B., Wang, Y., Niu, X., Tian, R., & Huang, H. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114917 · Cited by 54
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance
Ali, M., Kaltenbrun, E., Anderson, G. R., Stephens, S. J., Arena, S., Bardelli, A., Counter, C. M., & Wood, K. C. (2017) · Nature Communications · doi:10.1038/ncomms15617 · Cited by 43
“Although KRAS has been shown to play a central role in primary and acquired resistance to anti-EGFR therapy in CRC as well as in other therapeutic contexts, no effective pharmacological inhibitors of KRAS, or other RAS oncoproteins, have reached the clinic to date 35 .”
Abbott, J. R., Hodges, T. R., Daniels, R. N., Patel, P. A., Kennedy, J. P., Howes, J. E., Akan, D. T., Burns, M. C., Sai, J., Sobolik, T., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00360 · Cited by 40
Self-citationHuijberts, S. C. F. A., van Geel, R. M. J. M., van Brummelen, E. M. J., Opdam, F. L., Marchetti, S., Steeghs, N., Pulleman, S. M., Thijssen, B., Rosing, H., Monkhorst, K., et al. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04066-4 · Cited by 48
Lee, H. W., Sa, J. K., Gualberto, A., Scholz, C. R., Sung, H. H., Jeong, B. C., Choi, H. Y., Kwon, G. Y., & Park, S. H. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1246 · Cited by 47
“Although targeted inhibition of RAS-based signaling is not yet available clinically (16), FTI is known to decrease RAS translocation to membranes and reduce its ability to mediate activation of downstream effectors in”
BackgroundEfforts to Develop KRAS Inhibitors
Holderfield, M. (2018) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a031864 · Cited by 43
“Similar studies have since been performed by other groups using different nucleotide exchange assays, but all nucleotide exchange inhibitors typically suffer from low affinity for RAS (Cox et al. 2014) and often lack activity in cells.”
ResultTargeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides
Wang, D., Wang, Q., Wang, Y., Chen, P., Lu, X., Jia, F., Sun, Y., Sun, T., Zhang, L., Che, F., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2113180119 · Cited by 43
Metadata
- Authors
- Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- Vanderbilt University (US)
- Dana-Farber Cancer Institute (US)
- National Cancer Institute (US)
- Corresponding author
- Der, Channing J.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-10-17
- Volume
- 13
- Issue
- 11
- Pages
- 828-851
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- PMC
- PMC4355017
- OpenAlex
- W2081990599
- Cited by
- 1,997
- References
- 231
- Citations by year
- 2026: 134 · 2025: 160 · 2024: 194 · 2023: 185 · 2022: 213 · 2021: 237 · 2020: 204 · 2019: 166 · 2018: 156 · 2017: 166 · 2016: 106 · 2015: 71 · 2014: 2
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (DP1OD006933, 5r01ca042978-30)
- U.S. Public Health Service (P50A095103-12)
- National Cancer Institute (P50CA127003, CA042978, R01CA175747, DP1CA174419, P50CA095103, CA175747, R01-CA042978, R21CA179193, RC2CA148375, CA179193, R01CA157490)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- oncogenic Ras, RAS inhibitors, undruggable targets, synthetic lethality, RAS-mutant cancers, anticancer drug discovery, Ras signaling
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Signal Transduction, Oncogene Proteins, ras Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.